GlaxoSmithKline and its Swiss partner Actelion have announced they are stopping development of an insomia treatment.
Actelion said the decision followed a review of data from clinical trials of the drug, almorexant. There had already been some safety concerns over the treatment, so the news is not exactly a major surprise.
http://www.guardian.co.uk/business/marketforceslive/2011/jan/28/glaxo-slips-insomnia-setback?
Actelion said the decision followed a review of data from clinical trials of the drug, almorexant. There had already been some safety concerns over the treatment, so the news is not exactly a major surprise.
http://www.guardian.co.uk/business/marketforceslive/2011/jan/28/glaxo-slips-insomnia-setback?
No comments:
Post a Comment